Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Kenvue

Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism

CNBC’s Jim Cramer warned Tuesday that President Donald Trump is creating a “nightmare of potential litigation” for consumer health giant Kenvue Inc. (NYSE:KVUE), sending the company's stock tumbling.

Benzinga

Nvidia, Kenvue, Rivian, MicroCloud Hologram And Opendoor: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks closed higher on Monday, with the Dow Jones Industrial Average edging up 0.14% to 46,381.54. The SP 500 added 0.4% to finish at 6,693.75, while the Nasdaq climbed 0.7% to 22,788.98.These are the top stocks that gained the attention of retail traders and investors through the day: Nvidia…

Benzinga

Trump urges pregnant women to limit taking Tylenol

He simultaneously touted a little-known drug called leucovorin as a way to decrease the symptoms of autism.

Axios

From analysis to the latest developments in health,
read the most diverse news in one place.

Tylenol-maker Kenvue's stock has lost a quarter of its value in 6 months as momentum grows for autism link despite repeated denials

Kenvue rebuked claims of a connection between autism and acetaminophen and said it is “deeply concerned with the health risk this poses for expecting mothers.”

Fortune

Kenvue Stock Is Sliding Today: What's Fueling The Sell-Off?

Shares of Kenvue Inc (NASDAQ:KVUE) are down Monday in anticipation of a negative Trump administration announcement about one of its products.

Benzinga

Tylenol maker Kenvue blasts Trump administration's autism claim

The over-the-counter drug is a critical product for Kenvue.

Axios

Jim Cramer's Warning On This Oil Stock: 'You Don't Want To Be In It'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said The Western Union Company (NYSE:WU) has got no growth.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Kenvue Pushes To Defend Pain Killer Tylenol Against Autism Claims Ahead Of Government Report

Kenvue Inc. (NYSE:KVUE) interim CEO Kirk Perry met privately this week with Health Secretary Robert F. Kennedy Jr. to argue that there is no proven link between the popular pain reliever Tylenol and autism.

Benzinga

Is Kenvue Stock Underperforming the Dow?

Despite Kenvue’s recent underperformance relative to the Dow, analysts remain moderately optimistic about the stock’s prospects.

Barchart

Tylenol maker's stock lost billions after a rumor linking the medicine to autism. Wall Street says buy the dip as one bank sees a 'major overreaction'

Canaccord Genuity went on social media to gauge the reaction. Even the MAHA crowd was mixed on this one.

Fortune

RFK Jr.'s planned report linking Tylenol to autism crashes shares of parent company Kenvue

RFK Jr. is preparing a report that will allegedly claim a link between prenatal Tylenol (acetaminophen) use and autism.

Fortune

Health Secretary RFK Jr to link Autism and Tylenol use in pregnancy sending company’s stock price spiraling

A report from the Department of Health and Human Services, touted by Trump and Kennedy in April, is expected to be published this month

The Independent UK

Tylenol In The Firing Line: RFK Jr. Autism Study Triggers Outrage, Market Rout And Big Pharma Panic

RFK Jr.'s autism study linking Tylenol in pregnancy to disorders sparks Big Pharma panic, political backlash and a fierce debate over corporate power.

International Business Times UK

RFK Jr. To Link Tylenol Use To Autism: Report

Health Secretary Robert F. Kennedy Jr. is preparing to release a report suggesting that the use of a common over-the-counter pain reliever during pregnancy may be tied to a higher risk of autism.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Kenvue Stock Outlook: Is Wall Street Bullish or Bearish?

Kenvue has outpaced the broader market over the past year, and analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Kenvue Stock Has Unusual Put Option Activity After Lower Q2 Sales and CEO Firing

Kenvue, which manufactures Band-Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO had left. Put options are showing unusually high volume today.

The Independent UK

Asian shares mostly decline as worries continue over Trump's tariffs

Asian shares are trading mostly lower as worries about President Donald Trump’s latest updates to his tariffs weighed on investor sentiments

Barchart

Tylenol-Maker Kenvue Launches Turnaround Plans. How Should You Play KVUE Stock Here?

Kenvue Inc ousted its chief executive and announced a strategic review on Monday. Jefferies says KVUE shares could rally to $27.

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors

The company will likely focus on off-loading smaller beauty brands.

Barchart

Is Kenvue Stock Outperforming the Nasdaq?

Despite its recent underperformance, Kenvue has outpaced the Nasdaq over the past year, and analysts remain moderately bullish on the stock’s prospects.

International Business Times UK

Kenvue Fights to Shield Brands Like Listerine and Tylenol Amid £112m Tariff Shock

Kenvue customers are expected to be prepared for price hikes as companies that sell directly to consumers grapple with rising costs.

Barchart

Are Wall Street Analysts Predicting Kenvue Stock Will Climb or Sink?

Kenvue has outpaced the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

MarketBeat

2 Under-the-Radar Consumer Staples Stocks With Big Dividends

Edgewell and Kenvue are under-the-radar consumer staples stocks poised to gain as the U.S. dollar declines. Learn why they may boost your income portfolio.

Barchart

Is Wall Street Bullish or Bearish on Kenvue Stock?

Despite Kenvue trailing the broader market over the past year, Wall Street analysts maintain a moderately bullish outlook on the stock's potential.

Barchart

How Is Kenvue’s Stock Performance Compared to Other Consumer Defensive Stocks

With Kenvue slightly lagging behind other consumer defensive stocks over the past year, Wall Street remains cautiously optimistic about its prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.